Center-Authored Papers

Filters: Author is Balk, Steven P  [Clear All Filters]
2017
Zang T, Taplin M-E, Tamae D, Xie W, Mesaros C, Zhang Z, Bubley G, Montgomery B, Balk SP, Mostaghel EA et al..  2017.  Testicular vs adrenal sources of hydroxy-androgens in prostate cancer.. Endocrine-related cancer. 24(8):393-404. Abstract
Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck B, Sharifi N, Wright JL, Gulati R et al..  2017.  Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2016
Taplin M-E, McKay RR, Werner L, Mostaghel EA, Lis RT, Voznesensky O, Zhang Z, Marck B, Matsumoto AM, Domachevsky L et al..  2016.  A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, Mostaghel EA, Chi KN, Lin D, Sanda M et al..  2016.  Neoadjuvant Enzalutamide Prior to Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W et al..  2016.  ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 22(14):3672-82. Abstract
2015
Hsieh C-L, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M et al..  2015.  PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy.. Cancer research. 75(10):1944-8. Abstract
Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin M-E, Penning TM.  2015.  The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.. Chemico-biological interactions. 234:332-8. Abstract
2014
Yu Z, Chen S, Sowalsky AG, Voznesensky O, Mostaghel EA, Nelson PS, Cai C, Balk SP.  2014.  Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2011
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu SX, Brown M et al..  2011.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.. Cancer cell. 20(4):457-71. Abstract
Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon N, Wang H et al..  2011.  Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration Resistant Prostate Cancer and is Upregulated by Treatment with CYP17A1 Inhibitors.. Cancer research. 71(20):6503-13. Abstract